תפריט כתבה
Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy
FOX NEWS
00:02, עידכון: 00:16
Every participant in a new bowel cancer immunotherapy trial remained cancer-free nearly three years after receiving pembrolizumab before surgery.
